

Welcome!

Overcoming Compliance Concerns and Barriers to Patient Engagement

Presenters









Laura Perry

Vice President Cactus Life Sciences

Maarten Beekman, MD

Managing Director Medical Impact+

Lily Chu, MD, MSHS

Vice President The International Association for Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis

Katie MacTurk, MS

Executive Research Director Health Union

Today's Learning Objectives



Identify assets for guidance to relevant information related to patient engagement



Apply solutions for inclusion of the patient perspective in Medical Affairs deliverables and development of clinical trial protocols



Recognize best practices/key insights on how to work with patients in a compliant manner



Provide guidance in developing your patient engagement strategy at your organization

2022 Workshop and Benchmark of Key Findings



- 1. 25% of participants polled strongly agree and 75% agreed that their organization should do more than they are currently doing to become patient inclusive
- 2. The majority of participants reported that they do not work on any cocreation of education materials with patients, but would like to in the future
- 3. Compliance was the major hurdle in becoming a true patient centric company

Good Patient Engagement Practices®: How to Start or Enrich Your Patient Engagement Strategy & Organization Maarten Beekman, MD

Patient Engagement in my Company

- A. Is well-established, we have a clear organizational structure and standard operating procedures in place and involve patients/caregivers in all what we do
- B. Is reasonably established, we have a clear organizational structure in place, some standard operating procedures and involve patients/caregivers in most of what we do
- C. Is somewhat established, we have some individuals working with patients/caregivers, some standard operating procedures in place and sometimes involve patients in what we do
- D. Is not established, we don't have an organizational structure in place, no standard operating procedures and we don't involve patients in what we do

Conflict of Interest and Disclosures

- I don't have a conflict of interest
- "<u>Collaborative Patient Engagement: Mapping the Global Landscape</u>" by <u>PFMD</u> is licensed under <u>CC BY-NC-SA 4.0</u>. I have selected relevant material from the PFMD website, did not change any of the content and would like to thank and give credit to the authors and contributors of the relevant documents of PFMD in the hand-out.
- I have selected relevant material from the EUPATI website, did not change any of the content and would like to thank and give credit to the authors and contributors of the relevant documents from EUPATI in the hand-out.
- I have selected relevant material from the PARADIGM website, did not change any of the content and would like to thank and give credit to the authors and contributors of the relevant documents from PARADIGM in the hand-out.



The main reason for being for Medical Affairs is to catalyze a change in clinical practice and/or policy based on robust science and real-world experience with the ultimate goal to provide better lives to people living with a disease (and to their caregivers)

Therefore, it is of utmost importance that Pharma and Biotech companies engage with patients (and their caregivers) to ensure these better outcomes

The reality is that there are still many Pharma and Biotech companies without a strong Patient Engagement strategy fully implemented, often as a result of perceived compliance risks

But not engaging with patients (and their caregivers) may become a bigger risk than engaging with them. With the information in this presentation, you will find useful information, standards, documents and tools to compliantly start or enrich your Patient Engagement strategy and organization


For this presentation, I have consulted the websites of three organizations, all active in Patient Engagement:



PFMD: Patient Focused Medicine Development

PARADIGM: Patients Active in Research And Dialogues for an Improved Generation of Medicines

🗘 🗘 PARADIGM





EUPATI: EUropean Patients' Academy in Therapeutic Innovation

Medical Affairs Professional Society (MAPS) | 2023

Please consult the **downloadable hand-out** which contains links to all relevant documents

How do I start?

- Building trust with the patient and caregiver's community is a critical success factor in Patient Engagement. Pharma and Biotech companies should develop a transparant framework with a clear description of roles and responsibilities, quality measures and ways of working.
- The following resources are recommended to use as a foundation on which to build your Patient Engagement strategy and operations:







How do I know we have the right capabilities to engage with patients?


- Understanding the capabilities needed to ensure quality and effective engagement with patients and caregivers is also a critical success factor in Patient Engagement.
- Pharma and Biotech companies should perform a thorough assessment of the available capabilities within the companies as well as a proper gap analysis. Training and/or acquisition of talent may be needed to ensure the right capabilities for Patient Engagement.

The following resource is recommended:



This tool provides recommendations on the competencies (understood as knowledge, skills and behaviours) and resources that each stakeholder organisation should aspire to have in place in order to plan, implement and evaluate meaningful and sustainable Patient Engagement activities across the medicines lifecycle.

Are their practical guidance's available that will help me to accelerate my Patient Engagement activities?



The EUPATI Guidance Document in this article aims at providing recommendations for ground rules and proposals for the integration of patient involvement across the entire process of medicines R&D in the pharmaceutical industry

And outlines specific activities where patients can be involved and influence future medicines research and development

Are their practical guidances available that will help me to accelerate my Patient Engagement activities?

How-To Guides for Patient Engagemen

(COA) strategy

'How-To' Guide on patient

engagement in the development

of a Clinical Outcome Assessment

PFMD developed a number of practical "**How To Guides" for Patient Engagement** that aim to provide specific support in Patient Engagement efforts, on key activities across the medicine development lifecycle

How-to guide for How-to guide for patient engagement in

the early discovery and preclinical phases

This How-To guide is part of a series of PRMD How-To guides hat have been co-created in a multi-stakeholder environment built with the Patient Engagement Quality Guidance as a tarting point. All How-To's are connected and provide a full set of instructions on how to involve patients across the research, sevelopment, and delivery of medicines



made with

Bow-To Guides for Patient Focused Patient Engagement

Plain language summaries (PLS) of peer-reviewed publications and conference presentations: practical 'How-To' Guide for multi-stakeholder co-creation



This How-To guide is part of a series of PRMD How-To guides that howe been co-created in a multi-stakeholder environment built with the Patient Engagement Quality Guidance as a starting point. All How-To's connected and provide a full set of instructions on how to involve patients across the research, development, and delivery of medicines.

How-To Guides for Patient Engagement

How-to Guide on Patient Engagement in Clinical Trial Protocol Design





Are there examples of Best Practices in Patient Engagement?


PFMD published three "Books of Good Practices".

If you are a starter in Patient Engagement, this book can offer you guidance and ideas on how to get it right. This tool can also be used to reach a common agreement about what is "good practice" in Patient Engagement.

The examples in the books demonstrate the quality and impact of the Patient Engagement activities:








Are there examples of Best Practices in Patient Engagement?

The **Patient Engagement Synapse** is an online tool to capture and map key information from Patient Engagement initiatives across the globe. The below screenshot of the countries allows you on the website to discover some of the most active organizations, people, initiatives and resources in Patient Engagement:



Conclusions and Recommendations

	٦
L	J.
_	

There is a wealth of information and guidance available on how to engage with patients in a compliant way, so **no need to re-invent the wheel**, just steal shamelessly!




Collaborate with your cross-functional colleagues, like Compliance and Legal, to develop your own standards and procedures and integrate Good Patient Engagement Practice (GPEP) as part of your GxP management system



Please **download the hand-out** where you can find all the relevant links to the documents I discussed (and many more!)

Helpful Guide with Resources Discussed



Maarten Beekman, MD

This link will be available on MAPS website by Monday.

For questions and/or feedback, please email: maartenjbeekman@gmail.com




Overcoming Barriers to Patient / Caregiver-Engaged Research Lily Chu, MD, MSHS

Conflict of Interest and Disclosures

NO financial conflicts of interest to disclose

Contents of this talk are solely my own thoughts and opinions. They do not necessarily represent the official views of the International Association for Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (IACFS/ME).

What is patient/ caregiver (PC)-engaged research?



"Research conducted **by/ with** PCs not only **to/ for** them" Why?

Lead to effective, practical, acceptable treatments Generate new ideas Improve patient recruitment/ retention Meet public, regulatory, funder requirements

Survey responders : ME/CFS and long COVID

- Community dismissed, ignored
- UK PACE: \$6 million/ time wasted; FOIA lawsuit
- Private PC e-group; personal contacts
- Active in clinical care, research, advocacy
- 80% involved in research before

Which group do you identify with most?

PC = patient/caregivers
PC - L = PCs leaders/ advocates
PC - P = PC & work in science/health field

N = 2326.1% PC-P 34.8% PC 30.4% PC-L

Polling Question #2:

What do PCs believe to be barriers to engagement?

What do PCs believe to be barriers to engagement?

cactuslifesciences@gmail.com (not shared) Switch account
* Required

Which of the following have been/ are reasons that would discourage you (and/ * or others) from being involved in studies? Reasons may not be ones that affect you personally but that you have heard/ read from other patients and caregivers. Choose all the reasons you believe apply.

Not invited to give input

Lack of medical/ scientific knowledge

Concerns about lack of knowledge

Feelings about not being "right" person to give input

Unclear information about what is expected, activities, etc.

Lack of trust in the people/ organization(s) asking for the input.

Doubt involvement will have impact

Doubt study will yield useful results

Health challenges (e.g. fatigue, unpredictable flares, pain)

Lack of time

Competing obligations (e.g. work, school)

Lack of incentives (e.g. financial, public acknowledgement)


Other:

Submit

Clear form

 \odot


What discourages you/ others from engaging?



OTHER OBLIGATIONS (WORK, SCHOOL) LACK OT TIME **HEALTH CHALLENGES DOUBT STUDY VALUE** DOUBT INVOLVEMENT IMPACT LACK OF TRUST IN ORGANIZERS **UNCLEAR INFORMATION NOT "RIGHT" PERSON CONCERNS ABOUT LACK** LACK OF MED/ SCI KNOWLEDGE **NOT ASKED FOR INPUT**

Reasons

What would encourage you (and/ or others) to be involved?



INVITED INPUT Solutions **AVAILABILTY OF TRAINING CLEAR EXPECTATIONS FLEXIBLE TIMING TAILORED INVOLVEMENT METHODS EARLY/ EXCLUSIVE ACCESS TO STUDY RESULTS COMMUNICATE IMPACT PUBLIC RECOGNITION APPROPRIATE INCENTIVES**

Ask! Consider what you want to know, who to ask.


Outline expectations and involvement

Offer appropriate medical/scientific training

Tailor participation methods and timing

Communicate impact. How did PC input affect study?

Which are you concerned about engaging with?



What are your concerns?

1. Profit Motive:

"What is the pharmaceutical company giving me?, They're motivated by profit, so I'm hesitant to trust their motivations."

"[C]ritical drugs [are not] readily available for people..... they do not care about the well being of people..... only care about profit and exploiting patients."

2. Lack of objectivity/ transparency:

"....concern that my name would be associated with a study which might involve the spinning of data.... by a for profit organization."

"My data would be used to support something I ethically disagree with and I would have no power or options to prevent it."

3. Data safety/ confidentiality:

"concerns about the objectivity of for-profit organizations and datasafety/confidentiality in studies involving for-profit groups."

Lessons from community-based participatory research (CPBR) → MA

"Collaborative approach; equitably involves all partners; recognizes strengths each brings."

- 1. Learn about history of community & research
- 2. Designate specific person(s) including leaders for PCs to contact
- 3. Use plain language, understandable terms
- 4. Ask PCs what they need to participate meaningfully
- 5. Conduct relationship "check-ups"



PCs are eager to participate as research partners.

Top barriers: not being asked for input, health challenges, doubts about involvement impact, lack of trust, unclear information.

There are many ways to overcome these barriers and build trust.



You think you need patient input? Now what... Katie MacTurk

Conflict of Interest and Disclosures

No financial conflicts of interest to disclose

Health Union is a company that, among other services and products, provides research / engagement services that can be used to obtain patient / caregiver input

You think you need patient input. Now what?

This part of the discussion will focus on key information you need to know and keep in mind at all phases of engagement




Most of discussion will focus here!

Key items to know prior to engagement



Medical Affairs Professional Society (MAPS) | 2023

Establishing Objective and Identifying Scope



Who do you want to talk with?

Identify Respondent Pool What characteristics do the patients / caregivers need to have?

How many individuals do you want to talk with?

What level of knowledge or expertise is required to answer questions?

Do patients / caregivers need to speak for just themselves – or speak to the experiences of many?

Everyday Patient

- Can speak only on behalf of self (/loved one)
- Little (known) expertise beyond experience with condition
- More representative of "real world" patients
- Typically need more respondents (depending on number of key subgroups)
- Patients living with metastatic lung cancer (and/or their caregivers) with similar characteristics as trial population (e.g., # of lines of therapy, necessary mutation status, etc.)
 - ~15 respondents (for qualitative discussions)



Expert / Trained Patient

- Can speak on behalf of other patients ("patient leader/advocate")
- Can know more about a specific topic and provide more informed opinions (e.g., knows how clinical trials work, familiar with drug development process, etc.)
- Typically need fewer respondents
- 2. Patients living with psoriasis who know the psoriasis treatment landscape, experiences & emotions of other patients; some knowledge of drug development a plus
 - ~2-5 respondents (for qualitative discussions)

2 Paths to engagement

Determine Path of Engagement How will you find the patients / caregivers?

How will you handle logistics of conversations, contracting, etc.?

What type of interaction will you have? (e.g., qualitative discussion, online survey, etc. – *not discussed here*)

Pharma engages via 3rd party

- 3rd party can: find patients, handle patient personal information and data, coordinate logistics, draft of materials to be used (screening form to qualify patients, questions to ask, etc.)
- Can be especially helpful when first starting out 3rd parties are experienced at 'translating' pharma questions into methodology, questioning for patients
- Pharma contracts with 3rd party, who will draft screening & discussion materials, recruit metastatic lung cancer patients & lead discussions about clinical trials, provide report of findings (*Pharma reviews, provides input, and approves all materials*)

Pharma engages directly

- Pharma identifies/finds patients (can also be with help of outside partner, like advocacy organizations)
- Contracts directly with patients for their time (& compensates appropriately)
- Members of company speak directly back & forth with patient(s)
- Pharma identifies 3 psoriasis patient advocates and contracts with each for an hourly consulting rate; company individuals talk with them ~every 3 months (either individually or as a group) to get input on various topics

Practices to ensure quality & compliance

Pharma Legal / Compliance Review

Standard practice for materials to be reviewed by medical / legal / compliance team to ensure proper disclosures, adherence to required guidelines, etc.

IRB Approval / Exemption (optional)

Can help those less familiar with patient engagement research feel comfortable that research is compliant with guidelines, industry-standard practices Recommended if you intend to publish results

Health Literacy Review (optional)

Team inside pharma company (or outside entity) can review all respondent-facing materials to ensure communication is at the appropriate level

Medical Affairs Professional Society (MAPS) | 2023

I'm about to talk with patients. Now what?

Make It Easy

Schedule discussions around patient schedules, conduct via web to further facilitate participation

Share Rationale

Tell patients the impact of their participation: how will this help them? How will this help others?

Set Expectations Be clear about how long engagement will last, what topics will be covered, what patient will need to do/bring/share

Be Upfront, Transparent Tell patient in clear, straightforward terms: who will handle personal information, what will be shared with whom (data safety, confidentiality)

Emphasize openness, neutrality

Share that pharma representative is neutral – not there to change patient thoughts, just to hear *all* their thoughts / perspectives (even if negative or critical)

Keep in mind the key concerns about pharma from patients:

Profit motivation for actions

Lack of transparency

Data security/confidentiality

What to do now? Follow through!

With Patient <u>Re</u>spondents

Compensate as established at engagement initiation Be clear about any next steps / follow up Continue to establish company as trustworthy After

With Patients Broadly Take learnings from engagement and apply them! Improving patient experiences is the reason for engaging!

With Your Organization Document process and assess what worked, what didn't, & what could be done better to improve future engagements Have record of findings & share within organization

Make future patient engagements better

What is the impact of patient discussions?

Engaging with patients directly can be beneficial on multiple levels



Patients spoken with during engagement can feel heard, like pharma cares



Patients have improved experiences with pharma (e.g., better clinical trial experience [apart from experience with treatment itself])



More patients have access to new treatment given successful clinical trial

After

Barriers/facilitators to clinical trial enrollment

Category	Examples	
About the Study	general attitude towards research, study procedures	
About the Participant	age, gender, health issues	
About Information	confusing information, misconceptions	
About Others	altruism, media influence	
About Costs & Benefits	financial compensation	

Rodríguez-Torres E, González-Pérez MM, Díaz-Pérez C. Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews. 2021.

Based on today's webinar, please rate from 1-5 if you feel this information made you more prepared to act on the following:

- 1. Identify assets for guidance to relevant information related to patient engagement
- 2. Recognize best practices/key insights on how to work with patients in a compliant manner
- 3. Apply solution to inclusion of the patient perspective in Medical Affairs deliverables and development of clinical trial protocols
- 4. Provide guidance in developing your patient engagement strategy at your organization

Panel Discussion and Q&A

Thank you to the attendees and our panelists: Maarten Beekman, MD, Lily Chu, MD, MSHS, Katie MacTurk, MS and Laura Perry.

We hope the attendees have found this webinar instructional. This webinar recording and corresponding PowerPoint deck will be uploaded to the MAPS website Content Hub by next week. Questions that we did not have time to respond to will be posted later to LinkedIn with responses. This concludes the webinar.